| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Fatemeh Nouri Emamzadeh, David Allso. α-Synuclein Interacts with Lipoproteins in Plasma. Journal of molecular neuroscience : MN. vol 63. issue 2. 2018-06-19. PMID:28887769. |
parkinson's disease (pd) is an age-related neurodegenerative disorder characterized by dopaminergic neural cell death in the substantia nigra of the brain and α-synuclein (α-syn) accumulation in lewy bodies. |
2018-06-19 |
2023-08-13 |
human |
| Irene Lopez-Fabuel, Lucia Martin-Martin, Monica Resch-Beusher, Garikoitz Azkona, Rosario Sanchez-Pernaute, Juan P Bolaño. Mitochondrial respiratory chain disorganization in Parkinson's disease-relevant PINK1 and DJ1 mutants. Neurochemistry international. vol 109. 2018-06-13. PMID:28408307. |
brain mitochondrial complex i (ci) damage is associated with the loss of the dopaminergic neurons of the substantia nigra in parkinson's disease (pd) patients. |
2018-06-13 |
2023-08-13 |
Not clear |
| L M Shapoval, B S Kop'yak, O V Dmytrenko, V O Mayskiy, O P Mankivaska, V F Sagac. NO-ERGIC CONTROL OF BLOOD CIRCULATION IN THE MEDULLA OBLONGATA OF RATS WITH EXPERIMENTAL HEMIPARKINSONIZM UNDER EXPOSURE TO CONTINUOUS LIGHT. Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994). vol 62. issue 6. 2018-06-12. PMID:29762971. |
the study was conducted on rats with unilateral damage to dopaminergic (da) neurons in substantia nigra of the midbrain (experimental hemiparkinsonism). |
2018-06-12 |
2023-08-13 |
rat |
| Frances Theisen, Rebecca Leda, Vincent Pozorski, Jennifer M Oh, Nagesh Adluru, Rachel Wong, Ozioma Okonkwo, Douglas C Dean, Barbara B Bendlin, Sterling C Johnson, Andrew L Alexander, Catherine L Gallaghe. Evaluation of striatonigral connectivity using probabilistic tractography in Parkinson's disease. NeuroImage. Clinical. vol 16. 2018-06-08. PMID:28971007. |
the cardinal movement abnormalities of parkinson's disease (pd), including tremor, muscle rigidity, and reduced speed and frequency of movements, are caused by degeneration of dopaminergic neurons in the substantia nigra that project to the putamen, compromising information flow through frontal-subcortical circuits. |
2018-06-08 |
2023-08-13 |
Not clear |
| Jia Liu, Xue Wang, Yongquan Lu, Chunli Duan, Ge Gao, Lingling Lu, Hui Yan. Pink1 interacts with α-synuclein and abrogates α-synuclein-induced neurotoxicity by activating autophagy. Cell death & disease. vol 8. issue 9. 2018-06-05. PMID:28933786. |
parkinson's disease (pd) is one of the most common neurodegenerative diseases, characterized by degeneration of dopaminergic neurons in the substantia nigra. |
2018-06-05 |
2023-08-13 |
Not clear |
| Mahsa Rostamian Delavar, Masoud Baghi, Zahra Safaeinejad, Abbas Kiani-Esfahani, Kamran Ghaedi, Mohammad Hossein Nasr-Esfahan. Differential expression of miR-34a, miR-141, and miR-9 in MPP+-treated differentiated PC12 cells as a model of Parkinson's disease. Gene. vol 662. 2018-06-04. PMID:29631008. |
parkinson's disease (pd) is a debilitating neurodegenerative condition characterized by the loss of dopaminergic neurons in substantia nigra. |
2018-06-04 |
2023-08-13 |
Not clear |
| Hiroshi Ito, Hiroshi Kawaguchi, Fumitoshi Kodaka, Hiroyuki Takuwa, Yoko Ikoma, Hitoshi Shimada, Yasuyuki Kimura, Chie Seki, Hitoshi Kubo, Shiro Ishii, Harumasa Takano, Tetsuya Suhar. Normative data of dopaminergic neurotransmission functions in substantia nigra measured with MRI and PET: Neuromelanin, dopamine synthesis, dopamine transporters, and dopamine D NeuroImage. vol 158. 2018-06-01. PMID:28655632. |
normative data of dopaminergic neurotransmission functions in substantia nigra measured with mri and pet: neuromelanin, dopamine synthesis, dopamine transporters, and dopamine d the central dopaminergic system is of major importance in the pathophysiology of parkinson's disease, schizophrenia, and other neuropsychiatric disorders. |
2018-06-01 |
2023-08-13 |
Not clear |
| Sujung Yeo, Backil Sung, Yeon-Mi Hong, Maurits van den Noort, Peggy Bosch, Sook-Hyun Lee, Jongbeom Song, Sang-Kyun Park, Sabina Li. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells. Gene. vol 661. 2018-05-30. PMID:29604467. |
decreased expression of serum- and glucocorticoid-inducible kinase 1 (sgk1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the substantia nigra of chronic mptp-induced parkinsonism mice and in sh-sy5y cells. |
2018-05-30 |
2023-08-13 |
mouse |
| Sujung Yeo, Backil Sung, Yeon-Mi Hong, Maurits van den Noort, Peggy Bosch, Sook-Hyun Lee, Jongbeom Song, Sang-Kyun Park, Sabina Li. Decreased expression of serum- and glucocorticoid-inducible kinase 1 (SGK1) promotes alpha-synuclein increase related with down-regulation of dopaminergic cell in the Substantia Nigra of chronic MPTP-induced Parkinsonism mice and in SH-SY5Y cells. Gene. vol 661. 2018-05-30. PMID:29604467. |
parkinson's disease (pd) is a chronically progressive neurodegenerative disease, with its main pathological hallmarks being a dramatic loss of dopaminergic neurons predominantly in the substantia nigra (sn), and the formations of intracytoplasmic lewy bodies and dystrophic neurites. |
2018-05-30 |
2023-08-13 |
mouse |
| Wei-Lan Yin, Wei-Guo Yin, Bai-Sheng Huang, Li-Xiang W. Neuroprotective effects of lentivirus-mediated cystathionine-beta-synthase overexpression against 6-OHDA-induced parkinson's disease rats. Neuroscience letters. vol 657. 2018-05-28. PMID:28764908. |
parkinson's disease (pd) is age-related neurodegenerative disorder by a progressive loss of dopaminergic(da) neurons in the substantia nigra (sn) and striatum, which is at least partly associated with α-synuclein protein accumulation in these neurons. |
2018-05-28 |
2023-08-13 |
rat |
| Athanasios D Spathis, Xenophon Asvos, Despina Ziavra, Theodoros Karampelas, Stavros Topouzis, Zoe Cournia, Xiaobing Qing, Pavlos Alexakos, Lisa M Smits, Christina Dalla, Hardy J Rideout, Jens Christian Schwamborn, Constantin Tamvakopoulos, Demosthenes Fokas, Demetrios K Vassilati. Nurr1:RXRα heterodimer activation as monotherapy for Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. vol 114. issue 15. 2018-05-22. PMID:28348207. |
parkinson's disease (pd) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic (daergic) neurons in the substantia nigra and the gradual depletion of dopamine (da). |
2018-05-22 |
2023-08-13 |
mouse |
| Sarah Plum, Simone Steinbach, Johannes Attems, Sharon Keers, Peter Riederer, Manfred Gerlach, Caroline May, Katrin Marcu. Proteomic characterization of neuromelanin granules isolated from human substantia nigra by laser-microdissection. Scientific reports. vol 6. 2018-05-16. PMID:27841354. |
neuromelanin is a complex polymer pigment found primarily in the dopaminergic neurons of human substantia nigra. |
2018-05-16 |
2023-08-13 |
human |
| Mi Wang, Wael Saasouh, Thomas Botsford, Allen Keebler, Andrew Zura, Michael S Benninger, Rafi Avitsia. Postoperative Stridor and Acute Respiratory Failure After Parkinson Disease Deep Brain Stimulator Placement: Case Report and Review of Literature. World neurosurgery. vol 111. 2018-05-15. PMID:29229347. |
parkinson disease (pd), a neurodegenerative disorder characterized by loss of dopaminergic neurons in the substantia nigra of the midbrain, is commonly thought of as a motion disorder, but it can have significant effect on the respiratory system. |
2018-05-15 |
2023-08-13 |
Not clear |
| Ivan Carrera, Lucia Fernandez-Novoa, Carolina Sampedro, Ramon Cacabelo. Neuroprotective Effect of Atremorine in an Experimental Model of Parkinson's Disease. Current pharmaceutical design. vol 23. issue 18. 2018-05-09. PMID:28190394. |
this devastating disease is caused by the progressive degeneration of dopaminergic neurons in the substantia nigra. |
2018-05-09 |
2023-08-13 |
mouse |
| Xiaoni Zhan, Fengrui Li, Qiaohong Chu, Hao Pan. Effects of PQ's cytotoxicity on secretory vesicles in astroglia: Expression alternation of secretogranin II and its potential interaction with intracellular factors. Biochemical and biophysical research communications. vol 497. issue 2. 2018-05-09. PMID:29454966. |
it has been extensively characterized that paraquat (pq) selectively targets to the substantia nigra and exerts neurotoxic actions on dopaminergic neurons. |
2018-05-09 |
2023-08-13 |
Not clear |
| Jaishree Jalewa, Mohit Kumar Sharma, Simon Gengler, Christian Hölsche. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease. Neuropharmacology. vol 117. 2018-05-03. PMID:28223210. |
the number of th positive dopaminergic neurons in the substantia nigra was decreased by 6-ohda lesion and was increased by da-jc1 treatment. |
2018-05-03 |
2023-08-13 |
mouse |
| XiaoLong Hu, Qi Song, Xin Li, DanDan Li, Qiao Zhang, WeiHong Meng, QingChun Zha. Neuroprotective effects of Kukoamine A on neurotoxin-induced Parkinson's model through apoptosis inhibition and autophagy enhancement. Neuropharmacology. vol 117. 2018-05-03. PMID:28238714. |
parkinson's disease (pd) is characterized by the loss of dopaminergic neurons in substantia nigra (sn). |
2018-05-03 |
2023-08-13 |
Not clear |
| Yasmina Martí, Friederike Matthaeus, Thorsten Lau, Patrick Schlos. Methyl-4-phenylpyridinium (MPP+) differentially affects monoamine release and re-uptake in murine embryonic stem cell-derived dopaminergic and serotonergic neurons. Molecular and cellular neurosciences. vol 83. 2018-05-03. PMID:28673772. |
1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (mptp) is known to selectively damage dopaminergic (da) cells in the substantia nigra and to produce symptoms which are alike to those observed in parkinson's disease (pd). |
2018-05-03 |
2023-08-13 |
mouse |
| Jaung-Geng Lin, Chao-Jung Chen, Han-Bin Yang, Yi-Hung Chen, Shih-Ya Hun. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease. International journal of molecular sciences. vol 18. issue 9. 2018-05-03. PMID:28837077. |
the pathological hallmark of pd is a progressive loss of dopaminergic neurons in the substantia nigra (sn) pars compacta in the brain, ultimately resulting in severe striatal dopamine deficiency and the development of primary motor symptoms (e.g., resting tremor, bradykinesia) in pd. |
2018-05-03 |
2023-08-13 |
mouse |
| Hojin Kang, Rin Khang, Sangwoo Ham, Ga Ram Jeong, Hyojung Kim, Minkyung Jo, Byoung Dae Lee, Yun Il Lee, Areum Jo, ChiHu Park, Hyein Kim, Jeongkon Seo, Sun Ha Paek, Yun-Song Lee, Jeong-Yun Choi, Yunjong Lee, Joo-Ho Shi. Activation of the ATF2/CREB-PGC-1α pathway by metformin leads to dopaminergic neuroprotection. Oncotarget. vol 8. issue 30. 2018-04-23. PMID:28611284. |
the widely prescribed anti-diabetic medicine metformin is effective in preventing neurodegeneration in animal models; however, despite the significant potential of metformin for treating pd, the therapeutic effects and molecular mechanisms underlying dopaminergic neuroprotection by metformin are largely unknown.in this study, we found that metformin induced substantial proteomic changes, especially in metabolic and mitochondrial pathways in the substantia nigra (sn). |
2018-04-23 |
2023-08-13 |
Not clear |